Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors

Antiviral Therapy

Volumn 10, Issue 2, 2005, Pages 207-213

  Jones, Simon P ^a   Janneh, Omar ^a   Back, David J ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GLYCEROL 3 PHOSPHATE DEHYDROGENASE; INDINAVIR; INTERLEUKIN 6; MESSENGER RNA; NELFINAVIR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; SAQUINAVIR; STAVUDINE; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; FIBRINOLYTIC AGENT; SIGNAL PEPTIDE;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DEATH; CELL STRAIN 3T3; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; ANIMAL; BIOSYNTHESIS; CELL DIFFERENTIATION; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; GENETICS; METABOLISM; MOUSE; POLYMERASE CHAIN REACTION;

3T3 CELLS; ADIPOCYTES; ADIPONECTIN; ANIMALS; CELL DIFFERENTIATION; FIBRINOLYTIC AGENTS; HIV PROTEASE INHIBITORS; INDINAVIR; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; MICE; NELFINAVIR; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, MESSENGER; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA; ZIDOVUDINE;

EID: 22844452653     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Carr A & Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
2. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M & Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-F70.
3. Lo JC, Mulligan K, Tai VW, Algren H & Schambelan M. Body shape changes in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1998; 19:307-308.
4. Lo JC, Mulligan K, Tai VW, Algren H & Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998; 351:867-870.
5. Mallal SA, John M, Moore CB, James IR & McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
6. Nolan D, John M & Mallal S. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antiviral Therapy 2001; 6:145-160.
7. Maher B, Alfirevic A, Vilar KJ, Wilkins EG, Park BK & Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002; 16:2013-2018.
8. Nolan D, Moore C, Castley A, Sayer D, Mamotte C, John M, James I & Mallal S. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003; 17:121-123.
9. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C & Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50:1378-1388.
10. Dowell P, Flexner C, Kwiterovich PO & Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. Journal of Biological Chemistry 2000; 275:41325-41332.
11. Rudich A, Vanounou S, Riesenberg K, Porat M, Tirosh A, Harman-Boehm I, Greenberg AS, Schlaeffer F & Bashan N. The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes. Diabetes 2001; 50:1425-1431.
12. Hruz PW, Murata H, Qiu H & Mueckler M. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 2002; 51:937-942.
13. Murata H, Hruz PW & Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002; 16:859-863.
14. Janneh O, Hoggard PG, Tjia JF, Jones SP, Khoo SH, Maher B, Back DJ & Pirmohamed M. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antiviral Therapy 2003; 8:417-426.
15. Roche R, Poizot-Martin I, Yazidi CM, Compe H, Gastaut JA, Torresani J & Planells R. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 2002; 16:13-20.
16. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends in Endocrinology & Metabolism 2003; 14:137-145.
17. Hotamisligil GS. Molecular mechanisms of insulin resistance and the role of the adipocyte. International Journal of Obesity & Related Metabolic Disorders 2000; 24 (Suppl 4):S23-S27.
18. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luhoinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P & Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
19. Vigouroux C, Maachi M, Nguyen TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J & Bastard JP. Serum adipokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17:1503-1511.
20. Maher B, Lloyd J, Wilkins EGL, Fraser WD, Back DJ & Pirmohamed M. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF alpha and TNF-receptor levels, and on metabolic parameters. Antiviral Therapy 2004; 9:879-887.
21. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y & Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochemical & Biophysical Research Communications 1996; 221:286-289.
22. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T & Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochemical & Biophysical Research Communications 1999; 257:79-83.
23. Zietz B, Herfarth H, Paul G, Ehling A, Muller-Ladner U, Scholmerich J & Schaffler A. Adiponectin represents an independent cardiovascular risk factor predicting serum HDL-cholesterol levels in type 2 diabetes. FEBS Letters 2003;545:103-104.
24. Fasshauer M, Klein J, Neumann S, Eszlinger M & Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochemical & Biophysical Research Communications 2002; 290:1084-1089.
25. Fasshauer M, Kralisch S, Klier M, Lossner U, Bluher M, Klein J & Paschke R. Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes. Biochemical & Biophysical Research Communications 2003; 301:1045-1050.
26. Addy CL, Gavrila A, Tsiodras S, Brodovicz K, Karchmer AW & Mantzoros CS. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. Journal of Clinical Endocrinology & Metabolism 2003; 88:627-636.
27. Lihn AS, Richelsen B, Pedersen SB, Haugaard SB, Rathje GS, Madsbad S & Andersen O. Increased expression or TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. American Journal of Physiology. Endocrinology & Metabolism 2003; 285:E1072-1080.
28. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E & Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. Journal of Acquired Immune Deficiency Syndromes 2002; 31:514-520.
29. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T & Yki-Jarvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. Journal of Clinical Endocrinology & Metabolism 2003; 88:1907-1910.
30. Tong Q, Sankale JL, Hadigan CM, Tan G, Rosenberg ES, Kanki PJ, Grinspoon SK & Hotamisligil GS. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. Journal of Clinical Endocrinology & Metabolism 2003; 88:1559-1564.
31. Wentworth JM, Burris TP & Chatterjee VK. HIV protease inhibitors block human preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. Journal of Endocrinology 2000; 164:R7-R10.
32. Hansen MB, Nielsen SE & Berg K. Re-examination and further development of a precise and rapid dye method for measuring celf growth/cell kill. Journal of Immunological Methods 1989; 119:203-210.
33. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB & Kadowaki T. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nature Medicine 2002; 8:1288-1295.
34. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y & Brichard SM. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochemical & Biophysical Research Communications 2001; 288:1102-1107.
35. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI & Petersen KF. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51:797-802.
36. Moore GB, Chapman H, Holder JC, Lister CA, Piercy V, Smith SA & Clapham JC. Differential regulation of adipokine mRNAs by rosiglitazone in db/db mice. Biochemical & Biophysical Research Communications 2001; 286:735-741.
37. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S & Cooper DA; Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429-438.
38. Yki-Jarvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P & Hamsten A. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arteriosclerosis, Thrombosis & Vascular Biology 2003; 23:688-694.
39. Ruan H, Pownall HJ & Lodish HF. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappaB. Journal of Biological Chemistry 2003; 278:28181-28192.